Testosterone and "Age-Related Hypogonadism"--FDA Concerns
- PMID: 26287846
- PMCID: PMC8905399
- DOI: 10.1056/NEJMp1506632
Testosterone and "Age-Related Hypogonadism"--FDA Concerns
Figures
References
-
- FDA briefing document for the joint meeting for Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARMAC). Silver Spring, MD: FDA Advisory Committee, September 17, 2014 (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria...). - PubMed
-
- Wang C, Nieschlag E, Swerdloff R, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009;21:1–8. - PubMed
-
- Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001; 86:724–31. - PubMed
-
- Institute of Medicine. Testosterone and aging: clinical research directions. Washington, DC: National Academies Press, 2004. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources